Corporate Overview March 2026 NASDAQ: LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that ...

Core Viewpoint - Lantern Pharma confirms that Panna Sharma remains the President and CEO, refuting false claims made by an unverified third-party report [2][4]. Company Leadership - Panna Sharma continues to serve as President, CEO, and Director, actively leading the company's strategy and operations [3]. - The Board of Directors has not approved any changes to the CEO position, affirming their confidence in Sharma's leadership [5]. Response to Misinformation - The company is investigating the origin of the false report and is considering legal actions against those responsible for disseminating misleading information [6]. - Lantern urges investors to rely on official communications and warns against potential stock price manipulation through false information [5]. Upcoming Events - Lantern will host a webcast on March 30, 2026, to discuss the fourth quarter and fiscal year 2025 operating and financial results, led by Panna Sharma [7][11].

Core Viewpoint - Lantern Pharma Inc. will report its fourth quarter and fiscal year 2025 operating and financial results on March 30, 2026, at 4:30 PM ET, highlighting its focus on AI-driven cancer therapies using the RADR® platform [1][10]. Financial Results Announcement - The management will discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025, along with guidance on upcoming milestones, clinical trials, and developments of the RADR® AI platform [2]. Webcast Information - A webcast will be held for the earnings call, and registration is available through a provided link. A replay of the call will be accessible on the investor relations section of the company's website after the event [3]. Company Overview - Lantern Pharma is an AI-driven biotechnology company focused on the discovery, development, and commercialization of cancer therapies, utilizing its proprietary RADR® platform to enhance drug development timelines and improve patient outcomes [4].

Core Insights - Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026, focusing on its AI-driven oncology drug development [1] - The company’s RADR® platform has facilitated the development of LP-184 / STAR-001, a novel therapeutic candidate for CNS cancers, including recurrent glioblastoma and pediatric brain tumors [1] - STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation, highlighting its potential in treating rare conditions [1] Company Overview - Lantern Pharma is a clinical-stage biopharmaceutical company utilizing artificial intelligence and machine learning to enhance oncology drug discovery and development [1] - The RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug responses, and design more effective clinical trials [1] - The company’s pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations [1] Presentation Highlights - CEO Panna Sharma will discuss the application of RADR® in discovering novel combination therapies, selecting optimal cancer indications, identifying patient biomarkers, and elucidating the mechanism of action of STAR-001 during the summit [1] - The presentation will emphasize AI-driven insights that address challenges in treating aggressive brain cancers like glioblastoma and atypical teratoid/rhabdoid tumors (ATRT) [1]

Core Insights - Hoth Therapeutics is adopting Lantern Pharma's PredictBBB.ai platform, which boasts a 94% accuracy in predicting blood-brain barrier permeability, positioning the company at the forefront of AI-driven drug development [1][2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments aimed at improving patient quality of life [5] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [5] Strategic Impact - The integration of PredictBBB.ai allows Hoth to enhance precision in candidate selection, reduce development risks, and potentially create faster regulatory pathways for its drug pipeline [4] - The ability to cross the blood-brain barrier is identified as a critical success factor for drug candidates, and the AI tool is expected to streamline this process [4] Leadership Statements - Hoth's CEO, Robb Knie, highlighted the commitment to utilizing disruptive technologies like AI to drive efficiency and unlock new opportunities for patients and shareholders [5] - Lantern Pharma's CEO, Panna Sharma, expressed enthusiasm for the collaboration, noting the potential of PredictBBB.ai to accelerate CNS drug development [3]

Company Overview - Lantern Pharma is leveraging its AI platform, RADR®, to transform cancer drug discovery and development, aiming to reduce costs and accelerate timelines[5, 6] - The company has raised approximately $100 million in total capital since 2019[5] - RADR® can predict and stratify real-world patients for clinical trials with 88% accuracy[6] - Lantern has 12 disclosed and collaborative lead drug programs[11] Drug Development Programs - LP-300, targeting Non-Small Cell Lung Cancer (NSCLC) in never smokers, represents a $4+ billion global annual market potential and is currently in Phase 2 clinical trials[23, 24] - Initial Phase 2 trial data for LP-300 showed an 86% clinical benefit rate in the safety lead-in cohort[38, 43] - LP-184, targeting advanced solid tumors with DDR deficiencies, has a $14+ billion annual US market potential and is in Phase 1 clinical trials[54, 55] - LP-284, targeting B-cell Non-Hodgkin's Lymphomas (NHL), represents a $4 billion annual global market potential and is also in Phase 1 clinical trials[88, 89] AI Platform and Collaborations - Lantern's RADR® platform incorporates over 100 billion data points from 130K+ patient records and advanced ML algorithms[13] - The company has strategic collaborations with academic, research institutions, and biopharma companies to accelerate timelines and gain unique real-world insights[19, 20, 21]